Las vacunas antirrábicas del presente y del futuro

Abstract

Currently available antirabies vaccines prepared from either animal brains or embryonated eggs have the unavoidable disadvantage of products prepared in vivo; the bulk of antigenic material in the vaccine is not viral but cellular. The hazards associated with the use of such material are well known

Combined use of antiserum and vaccine as recommended by the WHO Expert Committee on Rabies has greatly reduced the mortality rate for persons severely exposed to bites by wild animansl, but at the cost of the added risk of postvaccinal reactions from administration of heterologous serum

Development of a tissue culture source of virus for vaccine production appears to be the most promising possibility for greater progress toward rabies control

Antirabies vaccine prepared with a human diploid cell strain (WI-38) has proved a very potent antigen when tested in monkeys

Attenuated live virus (Flury HEP) vaccine and beta-propiolactone inactivated vaccine prepared with the Pitman-Moore strain of rabies virus (both of tissue culture origin) have been compared with the conventional type of vaccine by serum neutralization tests and animal resistance to challenge with standard strain of rabies virus; Rhesus and African green monkeys have been used as test animals

Tissue culture vaccine administered in one or three doses has induced an earlier appearance of antibodies at a much higher titer, and has ...(AU